PFE

Special Report: “10 New Stock Ideas for an Old Rally”–first 7 picks

Special Report: “10 New Stock Ideas for an Old Rally”–first 7 picks

The Standard & Poor’s 500 Index had a banner first half of 2024 with the index climbing more than 17% as of June 30. But two-thirds of that gain is attributable to just six stocks: Nvidia (NVDA), Microsoft (MSFT), Alphabet (GOOG), Amazon.com (AMZN), Meta Platforms (META), and Apple (AAPL.).Track the performance of equal-weighted version of the S&P 500–rather than the commonly tracked index where the contribution of any stock to the index is weighted by market cap–and the index was up just 3.9% in the first half of 2024. For the second half of 2024 and looking ahead to 2024, I’m not so much worried about the fundamentals of this extraordinary rally as I am by a failure of market imagination Everybody owns the same 6 stocks. Hey, I get the excitement around these stocks and the boom in Artificial Intelligence. I share it. Which is why I own shares of Nvidia, Amazon, and Alphabet in my online portfolios. But there are 494 other stocks in the S&P 500. And 2000 stocks in the small-cap Russell 2000.(Up 9% in the first half of 2024.)After a rally that has recorded 30 new record highs for the S&P 500 just the first half of n 2024, some of that other 494–or 2000–are actually better stock buys, and likely to out perform the 6 stocks everybody owns from their current record high prices. But which ones? That’s what my Special Report: “10 New Stock Ideas for an Old Rally” is all about.

Saturday Night Quarterback says (on a Sunday), For the week ahead expect…

Saturday Night Quarterback says (on a Sunday), For the week ahead expect…

Earnings, earnings, earnings. From members of the Magnificent 7: Microsoft (MSFT), Amazon (AMZN), Meta Platforms (META) and Apple (AAPL). in the consumer sector from consumer stocks Starbucks (SBUX), McDonald’s (MCD), Mastercard (MA).From drug companies Pfizer (PFE), Moderna (MRNA) and Merck (MRK). And from Big Oil Chevron (CVX), ExxonMobil (XOM), Shell (SHEL), and BP (BP). Here’s what I’d watch for.

Please Watch My New YouTube Video: Trend of the Week Drug Stocks Aren’t a Safe Haven Anymore

Please Watch My New YouTube Video: Trend of the Week Drug Stocks Aren’t a Safe Haven Anymore

This week’s Trend of the Week is “Drug Stocks Aren’t a Safe Haven Anymore.” Drug stocks seem to have lost their safe haven status. As of September 20, the Health Care Select Sector SPDR ETF (XLV) was down 4.6% in the last month, and Pfizer (PFE) was down 7.55%. Why? Investors who were looking for safe havens may have decided they don’t need them any longer if the volatility continues to not be as bad as expected on the downside. Or many analysts cut their estimates with the signing of the Inflation Reduction Act, which took steps toward drug price negotiations for Medicare and Medicaid. Or since drug stocks have been falling maybe they’re no longer a safe haven. (And yes, that’s circular logic.) Some of the ETF dips can be attributed to one stock: Moderna (down 12.46% in the last month) which is considered by much of the market as a one-trick pony–a Covid stock. However, I’m adding Moderna to the Jubak Picks Volatility Portfolio on September 27 because the company has a pipeline full of new vaccines based on the success of their Covid vaccines. Overall, drug stocks may not be the safe havens that they once were but there are still selective buys in the sector.

Pfizer and Moderna to see higher profits from Covid vaccines

Pfizer and Moderna to see higher profits from Covid vaccines

The federal government has agreed to purchase 105 million doses of Pfizer-BioNTech’s rebooted vaccine for $3.2 billion, the Washington Post reported on Friday. At $30.50 a dose, that’s a premium over the initial contracts the government made for the original vaccine in 2020, when the vaccines were $19.50 per dose. the government is expected to sign a new contract with Moderna (MRNA) shortly. Pfizer (PFE) is a member of my Dividend Portfolio. The shares are up 35.14% since I added them to the portfolio on August 28, 2020. The stock is down 11.89% year-to-date for 2022 as of the close on Friday, July 22. However, they are up 4.40% in the last month. Pfizer pays a 3.12% dividend.

For such a scary day, the market was amazingly “normal”; look at what went up

For such a scary day, the market was amazingly “normal”; look at what went up

Of course, there’s nothing even vaguely normal about a day when a stock falls 43% and takes much of the market with it.Snap’s (SNAP) plunge did take some surprising candidates along for the ride. Tesla (TSLA) dropped 6.93% on yet more bad news on production in its Shanghai factory. Disney (DIS) fell 4.01% just because. SentinelOne (S) was lower by 8.11% since everyone knows that cybersecurity stocks are just a fad.
But on balance, on the green side (and yes, there was a green side to the market) the market did what markets are supposed to do in the face of bad news and an increase in fear.

Today it looks more like a bear market rally

Today it looks more like a bear market rally

In my weekend Saturday Night Quarterback I said that this week would, probably, answer the question of whether Friday’s big bounce was just a bounce, the start of a buy on the dip rally, or even a bear market rally with a bit of staying power. Two days into the week I think the market action is moving in favor of a bear market rally, one of those often quite powerful upside moves that punctuate extended bear markets.

Special Report: New World for Dividends Pick #1 Pfizer

Another pattern from Friday to suggest this is a bounce and not a bottom

I can’t find Big Pharma stock in the green during Friday’s big rally. Which makes me question the staying power of Friday’s move. If the day’s gains were the result of a market bottom, wouldn’t everything be up? Even the very defensive drug stocks? Not as much as the tech losers of 2022 but still if the market had bottomed I’d expect these stocks to be in the green too. More evidence, I think, for my thesis that Friday was the result of technical trading in an over-sold market.

Pfizer and Moderna to see higher profits from Covid vaccines

3 shots good; 4 shots better

Executives at Pfizer (PFE), which, remember, makes a Corona-19 vaccine–said yesterday, December 8, that the new Omicron Variant could increase the likelihood that people will need a fourth coronavirus vaccine dose earlier than expected.